Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs offers an extensive range of powerful recombinant antibodies targeting FOLR1, meticulously engineered for application in diverse immunological assays. Designed for high specificity and accuracy, these antibodies enable researchers to thoroughly investigate the role of FOLR1 across various biological processes, facilitating advancements in understanding and targeting this important protein in health and disease.
Folate Receptor 1 (FOLR1) is a cell surface protein that binds to folate, a B-vitamin essential for various biological processes. It is primarily expressed on the apical surface of epithelial cells in organs like the lung, kidney, and choroid plexus. However, its expression is significantly elevated in various solid tumors, such as high-grade osteosarcoma, breast cancer, ovarian cancer, and non-small cell lung cancer, making it a promising target for cancer diagnosis and treatment, especially for malignancies that primarily affect women.
Folate receptor 1; folate binding protein; FOLR; FR-alpha; FRα; FBP; NCFTD; folate receptor 1 (adult).
The protein encoded by this gene is a member of the folate receptor family. Members of this gene family bind folic acid and its reduced derivatives, and transport 5-methyltetrahydrofolate into cells. This gene product is a secreted protein that either anchors to membranes via a glycosyl-phosphatidylinositol linkage or exists in a soluble form. Mutations in this gene have been associated with neurodegeneration due to cerebral folate transport deficiency. Due to the presence of two promoters, multiple transcription start sites, and alternative splicing, multiple transcript variants encoding the same protein have been found for this gene.
Creative Biolabs presents an extensive range of recombinant antibodies specifically engineered for targeting FOLR1 with high precision. These versatile antibodies, available in multiple formats, boast remarkable specificity and binding strength, making them perfect for a wide array of experimental techniques such as WB, IP, IHC, ELISA, etc.
Table 1. Featured anti-FOLR1 recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
HPAB-0119-CN | Mouse Anti-FOLR1 Recombinant Antibody (HPAB-0119-CN) | Human | Mouse IgG1, κ | ELISA, FC, IHC, WB |
HPAB-0312-WJ | Mouse Anti-FOLR1 Recombinant Antibody (HPAB-0312-WJ) | Human | Mouse IgG2a | ELISA, IHC, FC |
HPAB-0118-CN | Mouse Anti-FOLR1 Recombinant Antibody (HPAB-0118-CN) | Human | Mouse IgG | ELISA, FC |
TAB-019CQ | Human Anti-FOLR1 Recombinant Antibody (TAB-019CQ) | Human, Cynomolgus | Human IgG1, κ | ELISA, WB, IHC |
TAB-020CQ | Mouse Anti-FOLR1 Recombinant Antibody (TAB-020CQ) | Human | Mouse IgG1 | ELISA, FC, IHC, WB, etc. |
Creative Biolabs specializes in the development of novel therapeutic solutions in the cutting-edge field of biotechnology. Our highly qualified team combines modern research processes with cutting-edge technology to provide customized solutions for a wide range of applications. We take pride in our dedication to excellence, ensuring that every product we offer gets the highest levels of quality and performance.
Fig.1 WB analysis of anti-FOLR1 antibody
(Cat# TAB-020CQ, Creative Biolabs).
Fig.2 ELISA analysis of anti-FOLR1 antibody
(Cat# TAB-020CQ, Creative Biolabs).
Fig.3 Dot Blot analysis of anti-FOLR1 antibody
(Cat# TAB-020CQ, Creative Biolabs).
Fig.4 WB analysis of anti-FOLR1 antibody
(Cat# TAB-113, Creative Biolabs).
Fig.5 SDS-PAGE analysis of anti-FOLR1 antibody
(Cat# TAB-113, Creative Biolabs).
Fig.6 SEC-HPLC analysis of anti-FOLR1 antibody
(Cat# TAB-113, Creative Biolabs).
Creative Biolabs adopts an unconventional genetic modification approach to generate customized antibodies that target the FOLR1 protein, allowing for the efficient synthesis of premium antibodies, and ensuring a constant and durable supply appropriate for a wide range of applications.
Featured Anti-FOLR1 Recombinant Antibody Production Platforms
Fig.7 Milligram-scale anti-FOLR1 recombinant antibody production.
Fig.8 Gram-scale anti-FOLR1 recombinant antibody production.
Creative Biolabs offers a diverse range of high-quality recombinant antibodies targeting FOLR1, meticulously designed to meet the unique needs of researchers. These antibodies come in various formats, ensuring flexibility and adaptability for different experimental applications.
Fig.9 Full-length anti-FOLR1 recombinant antibody production and modalities.
Table 2. Public drug targeting FOLR1.
Company | Research Phase | Classification | Condition |
Epsilogen (Originator) | Phase I/II |
Antibodies Cancer Immunotherapy |
Cancer, breast Cancer, lung Cancer, ovary Cancer, solid tumor |
Instil Bio (Originator) | Phase I |
Cancer Immunotherapy Tumor Infiltrating Lymphocytes (TILs) |
Cancer, kidney (renal cell carcinoma) Cancer, lung (non-small cell) (NSCLC) Cancer, ovary Cancer, solid tumor |
ImmunoGen (Originator) | Phase I |
Antibody-Drug Conjugates (ADCs) Bispecific Antibody Fusions Cancer Immunotherapy Fc Fusion Proteins Maytansinoids Polypeptides, from 41 AA Single-Chain V-Domain Antibody Fragment (scFv) |
Cancer, endometrium Cancer, lung (non-small cell) (NSCLC) Cancer, ovary Triple negative breast cancer |
University of Pennsylvania (Originator) | Phase I | Cell-Based Gene Therapy | Cancer, ovary (epithelial recurrent) |
Cancer Research UK Epsilogen King's College London (Originator) |
Phase I |
Cancer Immunotherapy Chimeric Monoclonal Antibodies |
Cancer, ovary Cancer, solid tumor |
Baxter Eisai (Originator) Eurofarma Laboratorios Eurofarma Laboratórios (Eurofarma Laboratorios) Ludwig Institute for Cancer Research (Originator) Morphotek (Eisai) |
Discontinued |
Cancer Immunotherapy Humanized Monoclonal Antibodies |
Cancer, lung (non-small cell) (NSCLC) Cancer, lung (non-small cell) (NSCLC) (adenocarcinoma) Cancer, ovary Cancer, ovary (epithelial) |
Fred Hutchinson Cancer Research Center (Originator) Seattle Children's Hospital (Originator) |
Preclinical |
Cancer Immunotherapy Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Second-Generation CAR) |
Osteosarcoma |
MD Anderson Cancer Center (Originator) | Preclinical |
Cancer Immunotherapy Fc Fusion Proteins Immunoconjugates Polypeptides, from 41 AA Proteases Single-Chain V-Domain Antibody Fragment (scFv) |
Cancer, ovary |
MD Anderson Cancer Center (Originator) | Preclinical |
Cancer Immunotherapy Fc Fusion Proteins Immunoconjugates Polypeptides, from 41 AA Proteases Single-Chain V-Domain Antibody Fragment (scFv) |
Cancer, ovary |
Miltenyi Biotec (Originator) | Preclinical |
Cancer Immunotherapy Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Second-Generation CAR) |
Cancer, ovary |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
Please contact us if you're looking for a high-quality anti-FOLR1 recombinant product.